These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 24935930

  • 1. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
    Suárez-Fueyo A, Rojas JM, Cariaga AE, García E, Steiner BH, Barber DF, Puri KD, Carrera AC.
    J Immunol; 2014 Jul 15; 193(2):544-54. PubMed ID: 24935930
    [Abstract] [Full Text] [Related]

  • 2. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec 15; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

  • 3. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
    Ji J, Fan H, Li F, Li X, Dong G, Gong W, Song Y, Liu F, Hua C, Tan R, Dou H, Hou Y.
    Immunol Lett; 2015 Dec 15; 168(2):355-65. PubMed ID: 26545567
    [Abstract] [Full Text] [Related]

  • 4. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.
    Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Rückle T, Schwarz MK, Rodríguez S, Martinez-A C, Balomenos D, Rommel C, Carrera AC.
    Nat Med; 2005 Sep 15; 11(9):933-5. PubMed ID: 16127435
    [Abstract] [Full Text] [Related]

  • 5. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):230-7. PubMed ID: 23712004
    [Abstract] [Full Text] [Related]

  • 6. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

  • 7. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death.
    Suárez-Fueyo A, Barber DF, Martínez-Ara J, Zea-Mendoza AC, Carrera AC.
    J Immunol; 2011 Sep 01; 187(5):2376-85. PubMed ID: 21810603
    [Abstract] [Full Text] [Related]

  • 8. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
    Rohraff DM, He Y, Farkash EA, Schonfeld M, Tsou PS, Sawalha AH.
    Arthritis Rheumatol; 2019 Oct 15; 71(10):1681-1690. PubMed ID: 31106974
    [Abstract] [Full Text] [Related]

  • 10. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice.
    Fujita Y, Fujii T, Mimori T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, Sakai T, Kawanami T, Tanaka M, Masaki Y, Fukushima T, Okazaki T, Umehara H.
    J Immunol; 2014 Feb 01; 192(3):979-84. PubMed ID: 24391210
    [Abstract] [Full Text] [Related]

  • 11. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Mason JL, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.
    J Immunol; 2011 Oct 01; 187(7):3840-53. PubMed ID: 21880982
    [Abstract] [Full Text] [Related]

  • 12. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
    Chuan W, Wu-qing W, Zhu-wen Y, Zuo L.
    Lupus; 2014 Sep 01; 23(10):994-1005. PubMed ID: 24756437
    [Abstract] [Full Text] [Related]

  • 13. (5R)-5-hydroxytriptolide ameliorates lupus nephritis in MRL/lpr mice by preventing infiltration of immune cells.
    Zhang LY, Li H, Wu YW, Cheng L, Yan YX, Yang XQ, Zhu FH, He SJ, Tang W, Zuo JP.
    Am J Physiol Renal Physiol; 2017 Apr 01; 312(4):F769-F777. PubMed ID: 28100505
    [Abstract] [Full Text] [Related]

  • 14. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
    Luo J, Niu X, Liu H, Zhang M, Chen M, Deng S.
    Mol Immunol; 2013 Dec 01; 56(4):574-82. PubMed ID: 23911415
    [Abstract] [Full Text] [Related]

  • 15. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
    Chalmers SA, Wen J, Shum J, Doerner J, Herlitz L, Putterman C.
    Clin Immunol; 2017 Dec 01; 185():100-108. PubMed ID: 27570219
    [Abstract] [Full Text] [Related]

  • 16. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 01; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 17. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice.
    Kadiombo AT, Maeshima A, Kayakabe K, Ikeuchi H, Sakairi T, Kaneko Y, Hiromura K, Nojima Y.
    Am J Physiol Renal Physiol; 2017 Feb 01; 312(2):F297-F304. PubMed ID: 27881396
    [Abstract] [Full Text] [Related]

  • 18. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice.
    Muraoka M, Hasegawa H, Kohno M, Inoue A, Miyazaki T, Terada M, Nose M, Yasukawa M.
    Arthritis Rheum; 2006 Nov 01; 54(11):3591-600. PubMed ID: 17075801
    [Abstract] [Full Text] [Related]

  • 19. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC, Zhang CM, Tang LQ, Liu ZP.
    Eur J Med Chem; 2018 May 10; 151():9-17. PubMed ID: 29601991
    [Abstract] [Full Text] [Related]

  • 20. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.
    J Rheumatol; 2002 Apr 10; 29(4):707-16. PubMed ID: 11950011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.